Clinical trials are a very important part of new drug research and development, and it is also an indispensable link
for each new drug before it is approved for production and market use.
In recent years, with the high enthusiasm for new drug research and development at home and abroad, the continuous increase in R&D investment of pharmaceutical companies, and the acceleration of new drug review and approval, a large number of new drugs have entered the clinical trial stage and began to usher in good news
.
The clinical trial of BUCHANG Pharmaceutical BC008-1A injection drug was approved
The clinical trial of BUCHANG Pharmaceutical BC008-1A injection drug was approved
Recently, Buchang Pharmaceutical announced that its subsidiary has obtained a notice of approval for clinical trials of BC008-1A injection drugs, and the main indication of the drug is advanced solid tumor
.
It is reported that BC008-1A injection (recombinant anti-PD-1/TIGIT humanized bispecific antibody injection) is a specific target PD-1 and TIGIT dual antibody drug, which can directly block the PD-1 and TIGIT signaling pathways, lift the inhibition of T lymphocytes, thereby facilitating the activation of T cells, achieving the effect of enhancing immune surveillance, recognition and killing of tumor cells, while blocking the potential synergy that PD-1 and TIGIT may have, in order to enhance the anti-tumor effect
。 At present, there is no approval for marketing
of similar dual-target drugs at home and abroad.
Zejing Pharmaceuticals Jacktinib hydrochloride tablets Phase II clinical trial was successful
Zejing Pharmaceuticals Jacktinib hydrochloride tablets Phase II clinical trial was successful
On September 14, Zejing Pharmaceutical announced the successful results
of the phase II clinical trial of the company's product, Jacktinib Hydrochloride Tablets for the Treatment of Active Ankylosing Spondylitis.
It is understood that Jacktinib hydrochloride is a new TYPE OFJAK inhibitor drug independently developed by Zejing Pharmaceutical, which belongs to Class 1 new drugs, which has independent intellectual property rights
of the product.
Jacktinib has a significant inhibitory effect
on Janus kinases including JAK1, JAK2, JAK3 and TYK2.
The clinical trial of the new drug LY 03015 of Luye Pharmaceutical was approved in the United States
The clinical trial of the new drug LY 03015 of Luye Pharmaceutical was approved in the United States
On September 13, Luye Pharmaceutical announced that the new drug LY 03015 in the central nervous system field of the group has been approved by the US Food and Drug Administration for clinical trials
.
According to the data, LY 03015 is an innovative small molecule compound product for the treatment of tardive dyskinesia (TD) and chorea (HD) independently developed by the
Group.
As a new generation of VMAT2 inhibitors, LY 03015 can alleviate the symptoms of tardive dyskinesia and Huntington's disease by inhibiting the release of dopamine (DA) from presynaptic neurons, avoiding DA stimulation of hypersensitive D2 receptors and not blocking the D2 receptors
of the postsynaptic membrane.
Ruiyuan Bio RY_SW01 Cell Injection will initiate Phase I clinical trials
Ruiyuan Bio RY_SW01 Cell Injection will initiate Phase I clinical trials
Jiangsu Ruiyuan Biotechnology Co.
, Ltd.
, a subsidiary of Jiangsu Lianhua Environmental Pharmaceutical Group Co.
, Ltd.
, has also obtained tacit clinical trial permission from the Drug Evaluation Center of the State Drug Administration for the first class of new drugs for the treatment of active lupus nephritis biological products ,RY_SW01 Cell Injection", which is expected to start phase I clinical trials
within this year.
Disclaimer: In no event shall the information or opinions expressed herein constitute investment advice
to any person.
